Epidemiological Patterns, Temporal Trends in Management and Long-Term Outcomes in Testicular Cancer: a 30-Year Single Center Experience

30-year Spanish single-center data: men over 40 at diagnosis quadrupled from 7% to 29%, and 10-year cause-specific survival reached 97%

Journal: Clinical & Translational Oncology | Published: 2025-10-13 | Type: Retrospective cohort | PMID: 41083654 Authors: Capdevila Patricia, Aparicio Urtasun Jorge (Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain) Funding/COI: Funding not listed. Authors declare no conflicts of interest.

Summary

A 30-year retrospective from a single Spanish center tracked 277 men with testicular germ cell tumors (TGCTs) and found rising incidence, an aging patient population, and a sustained shift away from aggressive adjuvant treatment — without sacrificing survival. The proportion of men aged ≥40 at diagnosis quadrupled over three decades, while seminoma incidence doubled relative to non-seminomatous disease. The headline survival numbers are excellent, but the 5% rate of second malignant neoplasms and the non-cancer mortality burden are the underreported story here.

Claims

• TGCT incidence increased significantly across the three 10-year periods (p < 0.05)
• Stage I diagnoses increased over time (p < 0.05), consistent with earlier detection
• Median age at diagnosis rose from 29 years (1994–2003) to 35 years (2014–2023)
• Proportion of patients aged ≥40 at diagnosis: 7.3% (1994–2003) → 28.6% (2014–2023), p < 0.001
• Seminoma incidence doubled: 37.8% of cases in period 1 vs. 55.4% in period 3 (p < 0.05); NSGCT remained stable at 44.6% in both periods
• Active surveillance for stage I disease increased significantly; adjuvant chemotherapy declined (p < 0.0005)
• 10-year cause-specific survival improved: 95.0% → 97.2%
• Overall survival stable at approximately 94%
• Contralateral testicular cancer occurred in 2.9% of patients
• Second malignant neoplasms (SMNs) occurred in 5.0% of patients
• Recurrence rates slightly decreased but the difference was not statistically significant
• Among advanced-stage patients (stages II–III), 71% had NSGCT; 27.6% of those presented embryonal carcinoma

Study Quality

This is a single-center retrospective spanning 30 years, which carries fundamental structural problems. Practice standards, documentation protocols, staging technology, and surveillance intensity all changed substantially between 1994 and 2023, making period-to-period comparisons vulnerable to secular confounding that the authors cannot fully control. The 277-patient sample is modest for detecting differences in low-frequency outcomes like SMNs (n = ~14) or late mortality. The authors excluded 18 patients for missing records and another 18 referred from outside for salvage chemotherapy — the latter group presumably represents higher-risk patients, and removing them likely flatters survival estimates.

Statistical methods are appropriate: Kaplan-Meier with log-rank comparisons, chi-squared and Fisher's exact tests for categorical data, Wilcoxon rank-sum for continuous variables. The authors pre-specified p < 0.05 and honestly reported that recurrence rate improvement did not reach statistical significance rather than framing it as a confirmed trend. No multivariable analysis was performed, so confounding by stage distribution, histology mix, or patient demographics across periods is unaddressed.

Red Flags

• Single center in Spain: generalizability to other health systems and ethnic populations is limited
• Retrospective design with 30-year span: early-period data quality cannot match later-period data quality
• Exclusion of salvage chemotherapy referrals removes the sickest patients, creating survival estimate bias
• Underpowered for rare outcomes: 277 patients is insufficient to draw robust conclusions about SMN rates or late non-cancer mortality
• No multivariable modeling to disentangle period effects from stage-shift or histology-shift effects
• Funding source not disclosed
• The Latin American demographic trend noted (1% → 9.8%) is interesting but is an observation without any accompanying analysis

Strengths

• Median follow-up of 119 months (range 5–362 months) captures late events including SMNs and second primaries that shorter studies miss
• Three structured, equal-length time periods enable systematic trend comparison
• Pathology reviewed locally by experienced genitourinary pathologists at the time of diagnosis
• Captures non-cancer mortality alongside cancer-specific mortality — a survivorship-relevant distinction most oncology retrospectives ignore
• Authors are transparent about non-significant findings rather than overselling them
• Manual verification of all clinical and pathological data cross-checked against original records

Verdict

This is competent descriptive epidemiology that confirms trends already documented in Nordic registries and larger national cohorts: TGCTs are appearing in older men, seminoma is rising, and less-aggressive management is preserving equivalent survival. None of this is new. The paper's specific contribution is the long follow-up combined with survivorship data — the 5% SMN rate and the non-cancer mortality burden are the numbers that deserve attention, because they make the case that a man who beats testicular cancer at 35 still needs monitoring at 55. The single-center design and lack of multivariable analysis limit what conclusions can be drawn beyond trend description. Useful for building a survivorship epidemiology argument; not the paper to cite on treatment efficacy.